ArticleCureus2025
Hemodynamic and Uterotonic Effects of Carbetocin Versus Oxytocin in a Cesarean Section With a High Risk of Postpartum Hemorrhage.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, particularly in developing countries. Effective uterotonic agents are crucial for minimizing blood loss and maintaining hemodynamic stability during deliveries. Carbetocin has emerged as a promising alternative to oxytocin for preventing PPH, especially in high-risk pregnancies. AIMS AND
objectivesThis study aimed to compare the efficacy of carbetocin and oxytocin in controlling intraoperative blood loss, maintaining uterine tone, and reducing the need for additional uterotonics in women undergoing cesarean section (CS) with a high risk of PPH. MATERIALS AND
methodsThis prospective case-control study was conducted on 200 pregnant women at high risk for PPH undergoing CS after obtaining written informed consent. Participants were randomly assigned to two groups. Group I (n = 100) received injection carbetocin (100 µg IV), while Group II (n = 100) received injection oxytocin (10 IU IV in 500 mL normal saline). The hemodynamic parameters of the participants, uterine tone, blood loss, and the need for additional uterotonics were recorded and analyzed.
resultsCarbetocin significantly reduced intraoperative blood loss, with 81 participants (81%) in the carbetocin group experiencing blood loss less than 500 mL compared to 54 participants (54%) in the oxytocin group. The need for additional uterotonics was significantly lower in the carbetocin group (13% vs. 43%; n = 100). Uterine tone was better in the carbetocin group both intraoperatively and two hours postoperatively (p < 0.0004), and the postoperative fall in hemoglobin was also less compared to the oxytocin group. Hemodynamic stability was maintained better in the carbetocin group, with fewer fluctuations in blood pressure.
conclusionCarbetocin was found to be more effective than oxytocin in managing high-risk cesarean deliveries, offering better control over intraoperative blood loss, maintaining uterine tone, and reducing the need for additional uterotonics. Its prolonged uterotonic effect and stable hemodynamic profile make it a superior choice for PPH prevention in CSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.